Kane Biotech: New Acquisition of FB Dermatology in Strategic Move
Deal News | Nov 12, 2024 | Globenewswire
Kane Biotech Inc., a biotechnology firm based in Winnipeg, Manitoba, has announced a pivotal agreement to acquire FB Dermatology S.R.L., an Italian company operating in the dermatology and wound care sector. This strategic acquisition aims to harness FB Dermatology's advanced Fluorescent Light Energy Technology for transformative applications in propelling Kane Biotech's position in the wound care and dermatology markets. This acquisition, involving a mixture of cash, common shares, and warrant purchases, strategically aligns with Kane Biotech's growth ambitions and market expansion. Expected commercial synergies include leveraging FB Dermatology's operational presence in Italy, Australia, and New Zealand to amplify Kane Biotech's wound care products internationally. The acquisition emphasizes Kane Biotech's dedication to innovation and value maximization for shareholders. The transaction, valued at $2.5 million subject to price adjustments, is anticipated to close by January 31, 2025, dependent on final regulatory, shareholder, and reorganizational approvals.
Sectors
- Biotechnology
- Healthcare
Geography
- Canada – Kane Biotech is based in Winnipeg, Manitoba, which places emphasis on the Canadian geography.
- Italy – FB Dermatology is incorporated in Italy, affecting the conditions and regulations relevant to the acquisition.
- Australia and New Zealand – Operations and market expansions discussed include Australia and New Zealand, involving sales and distribution networks pertinent to the transaction.
Industry
- Biotechnology – The article discusses Kane Biotech's acquisition of FB Dermatology, highlighting biotechnology applications in wound care and dermatology solutions.
- Healthcare – FB Dermatology operates in the dermatology sector, providing innovative treatments for skin conditions, making the healthcare industry relevant to the article.
Financials
- $200,000 – Initial cash component of the purchase price upon closing of the acquisition.
- 6,000,000 common shares – Part of the payment structure to FB Dermatology's shareholders, held in escrow and released over 36 months.
- 6,000,000 warrants – Issued to purchase Kane shares at $0.25 each, usable for 36 months.
- $920,000 – Cash payout 18 months post-closing, with an option for equivalent Kane Shares issuance.
- $1,380,000 – Final cash payout 36 months post-closing, also with an option for share issuance.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Kane Biotech Inc. | Bidding Company | Company | A biotechnology company focused on the commercialization of technologies that prevent and remove microbial biofilms, acquiring FB Dermatology. |
| FB Dermatology S.R.L. | Target Company | Company | An Italian biotechnology firm offering advanced dermatological solutions, known for patented FLETECH technology. |
| Marc Edwards | CEO, Kane Biotech Inc. | Person | President and CEO of Kane Biotech, leading the acquisition efforts. |
| Dr. Francesco Bellini | Majority Shareholder of FB Dermatology | Person | Majority shareholder of FB Dermatology, expressing commitment to Kane Biotech’s strategic growth post-acquisition. |